Brahma (BRM) is a novel anticancer gene, which is frequently inactivated in a variety of tumor types. Unlike many anticancer genes, BRM is not mutated, but rather epigenetically silenced. In addition, histone deacetylase complex (HDAC) inhibitors are known to reverse BRM silencing, but they also inactivate it via acetylation of its C-terminus. High-throughput screening has uncovered many compounds that are effective at pharmacologically restoring BRM and thereby inhibit cancer cell growth. As we do not know which specific proteins, if any, regulate BRM, we sought to identify the proteins, which underlie the epigenetic suppression of BRM. By selectively knocking down each HDAC, we found that HDAC3 and HDAC9 regulate BRM expression, whereas HDAC2 controls its acetylation. Similarly, we ectopically overexpressed 21 different histone acetyltransferases and found that KAT6A, KAT6B and KAT7 induce BRM expression, whereas KAT2B and KAT8 induce its acetylation. We also investigated the role of two transcription factors (TFs) linked to either BRM (GATA3) or HDAC9 (MEF2D) expression. Knockdown of either GATA3 and/or MEF2D downregulated HDAC9 and induced BRM. As targets for molecular biotherapy are typically uniquely, or simply differentially expressed in cancer cells, we also determined if any of these proteins are dysregulated. However, by sequencing, no mutations were found in any of these BRM-regulating HDACs, HATs or TFs. We selectively knocked down GATA3, MEF2D, HDAC3 and HDAC9, and found that each gene-specific knockdown induced growth inhibition. We observed that both GATA3 and HDAC9 were greatly overexpressed only in BRM-negative cell lines indicating that HDAC9 may be a good target for therapy. We also found that the mitogen-activated protein (MAP) kinase pathway regulates both BRM acetylation and BRM silencing as MAP kinase pathway inhibitors both induced BRM as well as caused BRM deacetylation. Together, these data identify a cadre of key proteins, which underlie the epigenetic regulation of BRM.
INTRODUCTION
SWI/SNF is a multimeric chromatin-remodeling complex first discovered in yeast as regulators of the SWItch and Sucrose NonFermenting phenotypes. 1, 2 This complex has since been shown to have a role in human gene expression, where it associates with and is required for the function of a diverse array of key cellular proteins and transcription factors (TFs), many of which have important roles in cancer development. 3, 4 The SWI/ SNF complex remodels chromatin such that regions and domains of DNA are made more accessible to cellular proteins that promote gene expression. [5] [6] [7] SWI/SNF therefore serves a catalytic role in facilitating and promoting gene expression. As a result of the large number of cellular proteins that are functionally linked to this complex, it is not surprising that this complex is frequently targeted and disrupted during cancer development. SWI/SNF has been linked to growth control, DNA repair, differentiation, development and cellular adhesion, and when SWI/SNF is rendered nonfunctional or impaired, these processes are also negatively impacted 3, 4 potentially promoting cancer development and progression.
The SWI/SNF complex is composed of one of two ATPase/ catalytic subunits, Brahma (BRM) or Brahma-related gene 1 (BRG1), along with 8-10 additional subunits. [8] [9] [10] Although the exact functions of the non-ATPase subunits are not yet completely understood, BRM and BRG1 function as the catalytic subunits that convert ATP energy into the mechanical motion necessary for the movement of histones within chromatin. 11, 12 These subunits also have distinct subdomains (Bromodomains) that are important for histone interactions, as well as an Rb-binding domain (containing the LXCXE sequence required to bind to Rb), and a helicase domain that is tied to the mechanistic function of the complex. 3 Both BRM and BRG1 bind Rb and facilitate Rb function. [13] [14] [15] [16] The loss of BRM and BRG1 renders Rb nonfunctional and represents another way that the Rb pathway can be potentially inactivated in cancer. Like Rb, p53 has also been functionally linked to BRG1 and possibly BRM. [17] [18] [19] In murine model systems, BRG1 is a lowpenetrance tumor suppressor while BRM loss does not induce tumors, but rather potentiates tumor development when combined with a carcinogen. [20] [21] [22] It has been suggested that each ATPase subunit can compensate for the loss of the other and lessen the impact of inactivation of one of these subunits. If true, this could potentially explain why BRM and BRG1 are often concomitantly lost in cancer cell lines and primary tumors. To date, however, the proteins that regulate BRM and BRG1 have not been established, and this lack of knowledge is an obstacle to understanding how to restore the expression of these genes in a manner that is clinically effective.
BRM and BRG1 are inactivated in 30-40% of lung cancer cell lines and 15-20% of primary lung tumors. [23] [24] [25] [26] [27] [28] Although BRG1 is mutated in 70-80% in cancer cell lines, 24, 28 the mechanism of BRG1 loss in primary tumors is not yet known and it appears not to involve genetic mutation. 29, 30 Like BRG1, BRM is silenced in 10-25% of a broad spectrum of solid tumor types, 25 similar to the frequency of KRAS, HER2, EGFR and ALK alterations in breast and lung cancers. However, unlike tumor-suppressor genes that are most often irreversibly mutated, BRM is not mutated, but rather reversibly suppressed. 25 Broad-acting histone deacetylase complex (HDAC) inhibitors such as suberoylanilide hydroxamic acid, Trichostatin A and butyrate readily induce BRM expression in BRM-deficient cell lines. 25, 31, 32 However, despite the ability of these compounds to induce BRM expression, they were also discovered to inactivate BRM via C-terminal acetylation 31 thereby precluding the use of these compounds for clinical restoration of BRM function. Hence, either epigenetic silencing or direct acetylation can disrupt BRM function.
Although the ability of HDAC inhibitors to reactivate BRM expression implicates HDACs in the regulation of BRM, few, if any, specific HDAC proteins have yet been linked to BRM regulation. Similarly, as histone acetyltransferases (HATs) are known to work in close concert with HDACs to regulate protein acetylation, what role this family of proteins has in the regulation of BRM is likewise unknown. We recently conducted a high-throughput screen and identified a number of different compounds that can restore BRM expression, 33 although the mechanism of BRM restoration still remains unclear. In order to identify any potential clinically effective drugs that could be used to restore BRM, it is necessary to understand the endogenous proteins involved in BRM silencing, as well as its inactivation. To accomplish this, we used a combination of short hairpin RNA (shRNA) knockdown, and transfection experiments in both BRM-positive and BRM-negative cell lines to determine the HDACs and HATs that control BRM expression; we used similar experiments to see which of these proteins control BRM acetylation. We uncovered two TFs, and using this RNA interference technology and transfection experimentation, we found that they sequentially regulate HDAC9 and then BRM expression. Although any gene that regulates BRM, could in theory, be targeted pharmacologically to clinically induce BRM, genes that are either specifically mutated or overexpressed in tumor specimens tend to make the best targets for therapy. Hence, we sequenced the identified BRMregulating HDACs, HATs and two TFs for any mutations or alterations that could explain the loss of BRM seen in cancer. We knocked down each of these BRM-linked genes to determine the impact on cellular growth when each of them was inhibited. Finally, as inhibitors to mitogen-activated protein kinase kinase 1 (MAP2K1; alias: MEK1) and mitogen-activated protein kinase 1 (MAPK1; alias: ERK) both induced BRM expression and caused BRM deacetylation, this indicates that BRM silencing and BRM acetylation are not in fact regulated by separate pathways, but instead are jointly regulated by the MAP kinase pathway. The results of these experiments illustrate the potential anticancer impact of pharmacologically targeting each of these genes and the complexity of the mechanism underlying BRM regulation.
RESULTS

HDAC3
and HDAC9 regulate BRM function and HDAC2 controls BRM acetylation Our initial goal was to determine which specific HDACs regulate BRM. We used both a specific HDAC-class 1 inhibitor and a pan-HDAC-class 2 inhibitor in order to help determine which HDACs are involved in BRM regulation and acetylation. We then used selective shRNAs to knock down and suppress each of the known 11 HDACs to specify which HDACs control BRM expression and which control BRM acetylation, because it is critical to determine the specific proteins that regulate each of these processes. To determine if a given HDAC controls BRM inactivation or BRM function, we evaluated, by western blot, the presence or absence of BRM acetylation and also demonstrated BRM function by showing the induction of BRM-dependent genes. BRM has been shown by several laboratories to be readily induced as well as inactivated via acetylation following treatment with pan-HDAC inhibitors such as: suberoylanilide hydroxamic acid (SAHA), Trichostatin A, Entinostat (MS-275) and butyrate. 25, 31, 32, 34 As these HDAC inhibitors nonspecifically inhibit both class 1 (HDACs 1, 2, 3 and 8) and class 2 (HDACs 4, 5, 6, 7, 9, 10 and 11) HDACs, these data indicate that one or more HDACs regulate BRM-but the findings do not implicate a particular enzyme. To identify which HDACs control BRM expression, we selectively knocked down each of the class 1 HDACs (HDAC1, HDAC2, HDAC3, HDAC8 and HDAC11; Supplementary Figure 1) as compared with control shRNA to define the role of these proteins, particularly HDAC3, in the induction of BRM. A comparison of BRM expression levels following the shRNAmediated knockdown of each of these class 1 HDACs demonstrates that BRM expression was only induced when HDAC3 was suppressed ( Figure 1a : BRM protein; Supplementary Figure 2 for BRM mRNA data). Although inhibition of HDAC3 restored BRM expression in deficient cell lines, it remained unclear whether this induced BRM was functional. Thus, as a marker of BRM activity as function of HDAC3 knockdown, we measured the expression of three BRM-dependent genes in both the SW13 and C33A cell lines that we have previously shown to be upregulated when BRM is functionally induced. 35 We conducted quantitative PCR (qPCR) for these genes in parental C33A and SW13 cell lines and daughter cell lines where anti-BRM shRNAs were introduced to suppress BRM induction. We observed induction of these BRM-dependent genes only in the parental cell lines where BRM was induced B7-to 15-fold ( Figure 1b) and not in the C33A and SW13 BRM-knockdown daughter cell lines. These data indicate that suppressing HDAC3 restores both BRM expression and function. By using a class 1 HDAC inhibitor, we found comparable results validating this shRNA data (Supplementary Figure 3) .
Along with others, we have previously shown that many of the nonspecific HDAC inhibitors that induce BRM expression (for example, MS-275, butyrate, CI994 and Trichostatin A) also induce BRM acetylation, resulting in BRM inactivation. 25, 31 To determine which of the class 1 HDACs are functionally linked to BRM acetylation, we knocked down each of the class 1 HDACs (HDAC1, HDAC2, HDAC3, HDAC8 and HDAC11) with gene specific shRNAs or scrambled shRNA (control) in the H441 and H661 cell lines. We noted that the induction of BRM acetylation was only observed when HDAC2 expression was inhibited (Figure 1c and Supplementary Figure 4 ). As class 2 HDACs are much more tissue specific in their expression compared with broadly expressed class 1 HDACs, we performed an initial screen for expression of each class 2 HDAC in four BRM-deficient cell lines (A427, SW13, C33A and H522). We found that HDAC4 and HDAC9, but not HDAC5, HDAC6, HDAC7 or HDAC10, were expressed in all four BRM-deficient cell lines (Supplementary Figure 5) . To determine if the class 2 HDACs (HDAC9 and/or HDAC4) affect BRM expression, we knocked down HDAC4 and HDAC9 with gene-specific shRNA (Supplementary Figure 1 ) and compared these results with scrambled shRNA in both SW13 and C33A cell lines. We observed that suppression of either HDAC4 or HDAC9 induced BRM protein ( Figure 1d ) and mRNA expression (Supplementary Figure 6 : BRM mRNA (B6-to 14-fold induction)). Using anti-HDAC4 or anti-HDAC9 shRNAs showed that the suppression of either HDAC4 or HDAC9 does not induce BRM acetylation (Figure 1d ). This finding is similar to knockdown with anti-HDAC3 (Figure 1a) , which also does not induce BRM acetylation. Of note, HDAC9 suppression, as compared with HDAC4, resulted in a significantly more robust induction of BRM protein (B4-fold more). These data were confirmed by using a pan-class 2 HDAC inhibitor ( Supplementary Figures 7 and 8 ).
MEF2D and GATA3 regulate BRM and HDAC9 The GATA and MEF2 families of TFs are known to be linked to the function and/or expression of HDACs 3, 4 and 9. [36] [37] [38] [39] Specifically,
Restoration and reactivation of BRM B Kahali et al HDAC9 expression is known to be controlled by MEF2D, whereas GATA2 and GATA3 are known to be involved in the regulation of BRM. 40 We therefore reasoned that these TFs might regulate BRM expression via their impact on either HDAC3 and/or HDAC9 expression. To investigate this, we used two complementary approaches: we first used shRNA knockdown of these genes in BRM-negative cell lines and second, we overexpressed these genes, via transfection, in BRM-positive cell lines. In addition, nuclear run-on experiments were used to determine if the levels of BRM and HDAC9 change because of an alteration in their transcription.
We conducted western blotting and qPCR to determine which of the MEF2 family members (MEF2A-D) are consistently expressed in BRM-deficient cell lines. We found that MEF2B and MEF2D were expressed in four BRM-negative and four BRMpositive lung cancer cell lines (Supplementary Figure 9) . Knocking down MEF2B and MEF2D using gene-specific shRNA as compared with control shRNAs revealed that only the silencing of MEF2D (Figure 2a ), induced BRM expression in both BRM-deficient cell lines, C33A and SW13. Moreover, the knockdown of MEF2D was also associated with a B5-fold decrease in HDAC9 expression (Figure 2b ). This is consistent with studies of the HDAC9 promoter that have shown that MEF2D binds to the HDAC9 promoter and drives its transcription. 39 In BRM-deficient C33A and SW13 cell lines, we next silenced the expression of GATA2 and GATA3 using shRNA and found that GATA3 knockdown as compared with cells transduced with scrambled shRNA (control) not only induced BRM mRNA expression about B10-fold, but also downregulated HDAC9 (B9-fold; Figures 2a and b) ; in comparison, HDAC9 expression was not changed appreciably when MEF2D or GATA3 was knocked down in the BRM-positive cell lines H157 and H441 (Figure 2b ). GATA2 and MEF2B knockdown had no effect on BRM expression in either the BRM-deficient cell lines (SW13 and C33A) or in the BRM-positive cell lines (H441 and H157). Similarly, shRNA knockdown of GATA2, GATA3, MEF2B or MEF2D had no effect on HDAC3. HDAC3 knockdown induced BRM-dependent genes, LGAL, DDX58, P8 and XAF1 between 7-and 15-fold in the parental cell lines, C33A and SW13, but not in the daughter cell lines where BRM expression has been suppressed by anti-BRM shRNA. (c) The expression of HDAC1, HDAC2, HDAC3, HDAC8 and HDAC11 was virally knocked down with the gene-specific shRNA in both H441 and H661 cell lines. BRM acetylation was observed only when HDAC2 expression was suppressed. (d) The suppression of HDAC4 yielded induction of BRM protein by western blotting, whereas silencing of HDAC9 by gene-specific shRNAs produced a qualitatively stronger induction of BRM. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading control; H460 was the positive control; the negative controls were the untreated parental cell lines, SW13 or C33A.
To further confirm a role for these genes in BRM regulation, the GATA3, MEF2D or HDAC9 genes were each transduced into the BRM-positive cell lines: H441 and H157. Regardless of whether GATA3, MEF2D or HDAC9 was introduced, the overexpression of each of these genes caused the downregulation of BRM mRNA in BRM-positive cell lines (Figures 2c; B5-, B2-and B6.5-fold decrease, respectively). In addition, we examined if GATA3, MEF2D and HDAC9 were able to affect the levels of each other's expression. Using qPCR, we observed that overexpression of either GATA3 or MEF2D induced HDAC9 expression ( Figure 2d ) an average of B17.5-and B4-fold, respectively, in H441 and H157 cells. In comparison, transfection of HDAC9 into these cells yielded B16-fold higher levels of HDAC9 mRNA by qPCR (Figure 2d ). In contrast, the overexpression of MEF2D and GATA3 did not significantly affect each other's expression in these cell lines. These data indicate that GATA3 and MEF2D can drive HDAC9 overexpression, consequently resulting in the suppression of BRM. This finding, however, does not rule out the possibility that one or both of these TFs can impact BRM expression independently of HDAC9.
Hence, to determine if GATA3 or MEF2D can regulate BRM dependently or independently of HDAC9, we knocked down GATA3 or MEF2D while driving the overexpression of HDAC9. After shRNA knockdown of GATA3 and MEF2D, we found that GATA3 and MEF2D mRNA expression was decreased B6-to 7-fold by qPCR, and their respective proteins were undetectable by western blot in either SW13 or C33A cell lines (Supplementary Figure 10) . In the presence of HDAC9 overexpression, we did not observe an Figure 2 . (a) MEF2D, GATA3 or both (MEF2D plus GATA3) were knocked down using gene-specific shRNA in the SW13 and C33A cell lines. After 72 h, protein lysates were harvested from both cell lines. By western blotting, we observed that the knockdown of MEF2D, GATA3 or both resulted in the induction of BRM. (b) HDAC9 mRNA expression was examined by qPCR as after MEF2D or GATA3 shRNA knockdown in both BRM-positive cell lines, H157 and H441, and BRM-negative cell lines, C33A and SW13. MEF2D and GATA3 knockdown caused B3-and B6.5-fold downregulation, respectively, in HDAC9 mRNA expression in the BRM-negative cell lines while no change in HDAC9 was observed in the BRM-positive cell lines. (c) Two BRM-positive cell lines, H441 and H157 were virally infected with MEF2D, GATA3 or HDAC9 gene. After 72 h of puromycin selection, we examined BRM expression by qPCR and found that forced expression of HDAC9, GATA3 or MEF2D decreased BRM mRNA expression by B7-, B5-and B3-fold in these cell lines, respectively. (d) We transfected in HDAC9, GATA3, MEF2D or control (empty vector) expression vectors into the BRM-positive cell lines H441 and H157. By qPCR, ectopic expression of HDAC9, MEF2D or GATA3 induced HDAC9 mRNA by 15-to 20-fold, 5-to 6-fold or 20-to 22-fold, respectively, as compared empty vector transfected controls in the H157 and H441 cell lines. (e) To determine if GATA3 and MEF2D can regulate BRM independently of HDAC9 expression, the BRM-deficient cell lines SW13 and C33A were transduced with either the HDAC9 gene (test) or an empty cassette (control) to achieve a relatively stable expression of HDAC9. qPCR of BRM expression in these cell lines showed that exogenous HDAC9-driven expression blocked BRM induction, when either GATA3 or MEF2D were also knocked down. In comparison, in the absence of exogenous HDAC9-driven expression (in cell lines infected with empty cassette), shRNA silencing of either GATA3 or MEF2D induced BRM mRNA approximately 7-to 10-fold. (f ) To determine how BRM is regulated by HDAC9, GATA3 and MEF2D, we knocked down each of these genes and then measured BRM transcription by nuclear run-on. Knockdown of HDAC9, GATA3 and MEF2D induced BRM transcription B20-, B14-and B12-fold, respectively, in both the SW13 and C33A cell lines.
induction in BRM expression when either MEF2D or GATA3 were knocked down (Figure 2e: data columns D and E). This is in contrast to the induction in BRM expression observed when either GATA3 or MEF2D was knocked down in the absence of HDAC9 ectopic overexpression. (Figure 2e : data columns B and C; B7-to 11-fold). These data support the hypothesis that GATA3 and MEF2D primarily regulate BRM expression by regulating HDAC9 expression. Finally, we conducted nuclear run-on experiments to examine BRM transcription rates after MEF2D, GATA3 or HDAC9 was knocked down in either SW13 or C33A cell lines. We found BRM transcription was increased between 12-and 20-fold when these three genes were individually suppressed (Figure 2f ), indicating that BRM transcription is indeed regulated by these proteins.
HATs can restore or inactivate BRM Our next question was to resolve the role of HATs in BRM regulation, because HATs have an antagonistic function to HDACs. We examined each HAT to determine which specific HAT(s) control BRM expression. This was accomplished by using complementary experimental approaches: we first transfected (overexpressed) each HAT in BRM-negative cell lines and second, in BRM-positive cell lines, we performed shRNA knockdown of those HATs linked to BRM regulation. Similar to the methods used for studying the HDACs, in order to determine which HATs control BRM acetylation, we transfected each HAT into BRM-positive cells and western blotted for the induction of BRM acetylation.
The balance between HDACs and HATs determines the final acetylation status of a protein, typically histones. 41 As inhibition of HDACs can restore BRM expression, 25 we reasoned that ectopic expression of one or more HATs might similarly reactivate BRM expression in BRM-deficient cell lines. To determine which HATs induce BRM, we transiently transfected 21 (Supplementary  Table 1 , includes a list of HATs tested and their sources) different HATs into both SW13 and C33A cell lines (Supplementary Table 2 shows the average fold increases for different HATs after transient transfection). Of these HATs, we found that ectopic expression of KAT6A, KAT6B or KAT7 specifically induced BRM mRNA (B15-to 25-fold; Figure 3a) . Conversely, we knocked down KAT6A, KAT6B or KAT7 in BRM-positive cell lines (H157, H460 or H661) and observed a decrease in B6-to 7-fold for each of these HAT mRNAs, as determined by qPCR (Supplementary Table 2 shows fold decreases of individual HATs mRNA after shRNA-mediated knockdown). We examined the impact of each HAT knockdown on BRM expression by qPCR and found a significant downregulation of BRM expression (Supplementary Figure 11) . We also introduced these same 21 HATs into the BRM-positive cell lines H661 and H441, which lack BRM acetylation, and immunoblotted for BRM acetylation. In both cell lines, we found that only KAT2B and KAT8 transfections led to the induction of BRM acetylation at levels comparable to BRM acetylation seen in the H460 cell line (Figure 3b) .
Alterations of TFs, HATs and HDACs linked to BRM regulation. To extend our findings, we next explored the extent to which any of the HATs, HDACs or TFs identified as having a role in BRM regulation are dysregulated, potentially leading to inappropriate BRM silencing or acetylation. To study this, we sequenced the mRNAs for each of the genes. We first sequenced HDAC3 and HDAC9 mRNA in four BRM-deficient cell lines and found no mutations or alterations in either HDAC. We also sequenced MEF2D, and although we did not find any mutations, we identified a unique splice variant involving exon 9 in the four BRM-negative cell lines sequenced that has not yet been reported. This alternate splice variant lacks the small 18-bp exon 9 and thus eliminates six amino acids from the primary protein sequence. The impact of this change is currently unknown. To determine if this alternative MEF2D splicing generally occurs in all cell lines or only in BRMdeficient cell lines, we compared these findings with those obtained from the sequencing of several BRM-positive cell lines and found no such splicing variant in any of the BRM-positive cell lines. We next examined the expression levels of GATA3 and MEF2D mRNA by qPCR in BRM-positive and BRM-negative cell lines to determine if changes in GATA3 or MEF2D mRNA expression correlate with BRM silencing. We found that GATA3, but not MEF2D, mRNA levels were overexpressed B10-to 12-fold (average) in BRM-deficient cell lines, as compared with BRMpositive cell lines ( Figure 4A ). We similarly investigated HDAC3 and HDAC9 mRNA levels in BRM-negative and BRM-positive cell lines and found that HDAC9, but not HDAC3, mRNA levels were B500-fold higher (on average) in BRM-deficient cell lines ( Figure 4B ) as compared with BRM-positive cell lines.
To determine if this overexpression of GATA3 and HDAC9 occurs in both primary lung tumors and lung cancer cell lines and correlates with BRM expression, we conducted qPCR and western blots for HDAC9 and GATA3 in BRM-negative versus BRM-positive non-small cell lung cancers. We found GATA3 and HDAC9 mRNA were expressed at higher levels in BRM-negative lung cancers as compared with BRM-positive tumors, B12-and B25-fold, respectively ( Figure 4C ). Similarly, we also found higher GATA3 and HDAC9 protein expression in BRM-negative tumors as opposed to that of BRM-positive tumors (Supplementary Figure 12) . To ensure that this differential expression of GATA3 and HDAC9 was derived from the tumor and not the normal tissue within the tumors samples, we immunohistochemically stained both BRM-positive and BRM-negative tumors for GATA3 and HDAC9 expression. We found that qualitatively, HDAC9 and GATA3 are expressed at higher levels in BRM-negative tumors as compared with BRM-positive tumors ( Figure 4D ). Of particular note, HDAC9 overexpression appears to occur in a variety of different cancer types, 42 indicating that HDAC9 might be a good target for therapy, similar to HER2 in breast cancer 43, 44 or epidermal growth factor receptor (EGFR) in lung cancer. 45 Targeting GATA3, MEF2D, HDAC3 or HDAC9 leads to BRM-dependent growth inhibition. BRM and the SWI/SNF complex are known to be essential co-factors for Rb-, p107-and p130-mediated growth inhibition. 46, 47 Multiple laboratories have shown that Rb is ineffective in arresting growth unless the SWI/SNF complex is active. 13, 15, 16, 48 Furthermore, either ectopic or pharmacologic restoration of BRM expression is sufficient to induce growth inhibition. 35 Hence, we next determined the impact on cell growth when we restored BRM expression by knocking down GATA3, MEF2D, HDAC3 and/or HDAC9.
We transduced the two BRM-deficient cell lines, C33A and SW13, with either: anti-GATA3, anti-MEF2D, anti-HDAC3 or anti-HDAC9 shRNA or with control (scrambled) shRNA and compared the growth of each of these cell lines. In both cell lines (C33A and SW13) we observed growth inhibition (B70% and B83%, respectively) when any of these genes was suppressed as compared with the scrambled shRNA (Figure 5a ). To demonstrate that the observed growth inhibition was BRMdependent in these cell lines, we performed essentially the same experiment except we also silenced BRM using anti-BRM shRNAs. In each of the BRM-suppressed cell lines, the growth inhibition was blunted, and their growth approached that of the control cell lines (Figure 5a ). Although compounds do not yet exist that specifically inhibit HDAC4 or HDAC9, the class 2 inhibitor MC1568, which targets multiple class 2 HDACs, was used in BRM-deficient cell lines that do not express HDAC 5, 6, 7, 8 or 10, to determine the impact of inhibiting HDAC4 and/or HDAC9. From our studies using this compound, we observed growth inhibition of 490% only in parental cell lines infected with control (scrambled) shRNA, compared with the daughter cell lines in which BRM expression had been silenced by BRM shRNA (Figure 5b) . In contrast to the class 2 HDACs, we identified a class 1 HDAC inhibitor (RGFP966) that was relatively specific for HDAC3. Treatment with this compound induced both BRM mRNA and BRM protein at approximately B5 mM (Supplementary Figure 13) . Similar to our results with HDAC3 shRNA-mediated knockdown (Figure 5a ), we observed marked growth inhibition in both BRM-negative cell lines (C33A and SW13 transduced with scrambled shRNA), when treated with this HDAC inhibitor (Figure 5b) . However, when BRM induction is blocked by anti-BRM shRNA, the observed RGFP966-mediated growth inhibition was blunted by B75% in these cell lines. Similarly, treatment with the pan-class 2 HDAC inhibitor, MC1568 also resulted in growth inhibition in the parental BRM-negative cell lines transduced with control shRNA, but not in the daughter cell lines harboring anti-BRM shRNA. Taken together, the selective targeting of HDAC3, HDAC9 or both, appears to be an effective means of inhibiting growth in BRMdeficient cancer cells.
MAP kinase pathway controls BRM induction and BRM acetylation.
To begin to understand the signal transduction pathways that control BRM silencing and/or BRM acetylation, we used our high-throughput screening assay 33 and tested the ability of a number of different kinase inhibitors to induce BRM. Using this luciferase reporter assay, we found that the compounds PD98059 and PD169316, which are known to be highly selective MAP2K1 and p38 MAPK1 inhibitors, respectively, 49 readily induced luciferase activity by B4-fold, which is an indirect measure of BRM expression. To verify BRM is induced, we treated two BRMdeficient cell lines with each of these compounds and found that BRM protein was induced by B11-and B6.5-fold by PD98059 and PD169316, respectively (Figure 6a and mRNA data in Supplementary Figure 14) . In addition, we tested two cell lines (H460 and H157) that have BRM acetylation (Figure 6b ). Application of these compounds not only induced BRM, but we observed that both of these compounds also reversed BRM acetylation (Figure 6b ). These data indicate that BRM acetylation and BRM silencing pathways are linked at the level of the MAP kinase pathway. We also attempted to validate these data using shRNA to various MAP kinases; however, the activation of BRM caused these cells to undergo growth arrest, and no cells could be propagated, which limited our analysis. We further tested the impact of using these MAP kinase inhibitors on GATA3 and HDAC9 expression. We found a complete downregulation of both proteins by western blot (Figure 6c ) in the BRM-deficient cell lines, C33A and SW13. Similarly, we found GATA3 and HDAC9 mRNAs were reduced by B44-and B16 000-fold (Supplementary Figure 15) , respectively, by these compounds. These data clearly indicate a connection between BRM regulation and the MAP kinase pathway. Interestingly in lung cancer, the MAP kinase pathway is known to be frequently activated by EGFR mutations (9%), 50 B-Raf (B3%) 51 or K-ras activation (25-30%), 52, 53 but BRM silencing occurs much less frequently, (B16-17%). As such, there must be other factors, which work in conjunction with the activated MAP kinase pathway to facilitate the downregulation of BRM.
DISCUSSION
We have shown that HDAC3 and HDAC9 regulate BRM expression, whereas HDAC2 controls BRM acetylation. As the balance between HATs and HDACs together controls the acetylation status of proteins, we also identified that HATs are involved in BRM regulation-in particular, we found that KAT6A, KAT6B and KAT7 control BRM expression, whereas KAT2B and KAT8 control BRM acetylation. We also wanted to know which of these proteins linked to BRM regulation might be mutated, overexpressed or Figure 5 . (a) Expression of HDAC9, GATA3 or MEF2D were each knocked down using gene-specific shRNA in both parental and daughter SW13 and C33A cell lines, whereas BRM was knocked down using anti-BRM shRNA in only the daughter cell lines. The knockdown of HDAC9, GATA3 or MEF2D in the parental SW13 and C33A resulted in cellular growth inhibition (65-90% inhibition). In comparison, these same knockdowns of either HDAC9, GATA3 or MEF2D in these daughter cell lines that had BRM suppressed with shRNA showed appreciably less inhibition (percentage inhibition 5-12%) in comparison with the parental cell lines. (b) The parental BRM-negative cell lines, C33A and SW13, or the daughter cell lines which harbor anti-BRM shRNA (to block BRM induction) were treated with either the HDAC3-specific inhibitor (RGFP966) at 5 mM or the pan-class 2 HDAC inhibitor (MC1568) at 5 mM. Whereas in the parental cell lines the treatment with either these compounds resulted in appreciable growth inhibition (70-80%) over 5 days, this observed growth inhibition was blunted in both daughter cell lines (5-10% inhibition). otherwise dysregulated. We found that GATA3 and HDAC9 are significantly overexpressed in cells that demonstrate BRM silencing. HDAC9 is a class 2 HDAC that is not ubiquitously expressed like the class 1 HDACs are, and it is overexpressed in BRM-negative cells. Based on these data, HDAC9 may represent a good target for therapy because its overexpression appears to be relatively specific for BRM-negative tumor cells. Finally, we show that the inhibition of HDAC9, either pharmacologically or by shRNA, results in growth inhibition. Together, these findings define the proteins underlying BRM suppression and illustrate that at least one of these proteins, HDAC9, is a promising target for therapy.
In addition, to define which HATs and HDACs control BRM silencing and BRM acetylation, we also demonstrated that the MAP kinase pathway is also part of the regulatory system and appears to function upstream of the HATs and HDACs. This is not the first report that the MAP kinase pathway controls BRM expression, as Muchardt et al. 54 showed that K-ras expression causes the downregulation of BRM, and BRM appears to conversely suppress K-ras when ectopically overexpressed. Furthermore, activated B-Raf in melanoma cell lines has been observed to downregulate BRM as well (Dr Del La Serna, University of Toledo, personal communication). Although the MAP kinase pathway is known to have a critical role in transducing growth signals, from our data, this pathway also appears to abrogate growth inhibition in part by facilitating the downregulation of BRM. We have illustrated our data in a diagram showing the complex interplay of HATs, HDACs, TFs and the MAP kinase pathway, all of which act to regulate BRM (Figure 7 ). Just how this occurs and what other proteins are necessary to link the MAP kinase pathway with HDACs/HATs still remains to be defined.
With its proven therapeutic efficacy and relatively low toxicity, targeted therapy is an invaluable approach in the treatment of cancer. Most effective molecular therapies target kinases; these targeted genes are usually specifically mutated or overexpressed, making them unique to cancer cells. Having a uniquely or differentially expressed target within a given cancer is key to the success of these molecular-based therapies. The targeting of kinases, especially cell-surface kinases such as EGFR, HER2 and vascular endothelial growth factor receptor (VEGFR), is wellestablished as a potent clinical therapy. However, cancer is not only driven by acquisition of oncogenic mutations that act as cellular 'gas pedals': it is also activated by the loss of cellular 'brakes'-tumor suppressors. Reactivation of suppressor genes as a form of targeted therapy has not yet been widely recognized because most of the tumor suppressors studied to date, such as Rb, p53, BRCA1 and phosphatase and tensin homolog deleted on chromosome 10, are also irreversibly inactivated in cancers by mutations. Unfortunately, gene therapy aimed at re-inserting normal tumor-suppressor genes back into deficient cancer cells has had relatively limited success. 55, 56 However, not all anticancer genes are mutated; there exists a group of genes that are epigenetically-and therefore reversibly-silenced in human cancer. 57 The prototype gene has been p16, which is frequently turned off via DNA methylation. 58 As such, inhibitors of chromatinremodeling proteins such as HDACs have proven effective in treating certain tumor types. 59, 60 However, despite the potential effectiveness of HDAC inhibitors in certain tumors, the anticancer genes targeted by HDACs have not yet been elucidated. In contrast, our research has led us to the discovery that BRM is, in fact, one of these genes that is not mutated, but reversibly silenced in cancer cells and that restoring its function in BRMdeficient cells potently inhibits growth. 33, 35, 61 In this work, we have identified several proteins that appear to be key regulators of BRM expression, specifically: GATA3, MEF2D, HDAC3 and HDAC9. Furthermore, the targeted inhibition of each of these proteins restores BRM expression and its potential anticancer effects.
These findings have important implications for the targeted therapy of BRM-deficient cancers. HDAC3 emerges as a particularly intriguing target, as it is appears to be involved in a number of human cancers, 62 and specific inhibitors already exist for this HDAC. However, as class 1 HDACs are more ubiquitously expressed, 63 targeting HDAC3 may have more toxic side effects. In comparison, HDAC9 appears to have several advantages if it was targeted for therapy. First, as a class 2 HDAC, HDAC9 expression is much more restricted. 63 Second, we and others have found HDAC9 to be overexpressed in many different cancer types, [64] [65] [66] [67] so its dysregulation may be a common theme in cancer. To date, there are no specific HDAC9 inhibitors that we could utilize to explore whether the abrogation of HDAC9 function would be clinically beneficial to patients. However, in this work, using a pan-HDAC class 2 inhibitor (MC1568) that likely inhibits only HDAC9 and HDAC4, BRM was induced, which in turn led to the arrest of cell growth. However, exposing patients to a pan-HDAC inhibitor would also likely have unintended side effects. In addition, as the apparent effective concentration for this compound to induce BRM is in the micromolar range, this would necessarily preclude the use of such drugs for the purpose of inhibiting HDAC9 as it is difficult to achieve such high drug levels in humans. 68 As such, our findings demonstrate the potential utility of developing potent inhibitors (in the low nanomolar range) specific to HDAC9 and testing their clinical application in BRM-deficient cancers.
GATA3 and MEF2D also appear to be restricted in their distribution of tissue expression and not ubiquitously expressed, like the class 1 HDACs. Although MEF2D is not mutated or overexpressed in BRM-deficient cell lines, we found a yetunreported splice variant that might impact its function. In addition, MEF2D could be aberrantly functioning because of defective post-translational modifications, which are known to regulate its function. 38, 69, 70 Although MEF2D appears to be tissue restricted in its expression, targeting MEF2D therapeutically might MAP kinase drives GATA3 expression, which in turn, drives HDAC9 expression in conjunction with MEF2D. The overexpressed HDAC9 likely forms a complex with HDAC3 that blocks BRM transcription. The lysine acetyl transferases, KAT6A, -6B and -7 work in the opposite manner whereby their activity results in inducing BRM protein. Post-translational regulation: BRM protein can be posttranslationally modified and inactivated by acetylation. As shown on the right side of this figure, BRM protein can either be acetylated (non-functional) or non-acetylated (functional). HDAC2 serves to remove these acetyl groups from BRM thus activating the protein, whereas KATs 2B and 8 acetylate BRM and inactivate it. The MAP kinase pathway also functions to induce BRM acetylation by acting on KAT2B/8 and/or HDAC2. Therefore, the MAP kinase pathway controls both the induction and acetylation of BRM.
be difficult to accomplish without producing significant side effects because it is neither overexpressed nor mutated like other currently used targeted therapies. In contrast to MEF2D, GATA3 is overexpressed in a variety of tumor types 71, 72 including BRMdeficient lung cancers. Our work shows that elevated GATA3 expression drives HDAC9 overexpression such that GATA3 is in large part indirectly linked to the suppression of BRM via HDAC9 overexpression. Sequencing GATA3 failed to reveal any mutations, although like MEF2D, GATA3 function could be impacted by aberrant post-translational modifications. [73] [74] [75] As such, either GATA3 or HDAC9 could be targeted for therapy as a means to restore the anticancer effect mediated by BRM. The next step will be to develop specific GATA3 and HDAC9 screening assays and use them to determine which BRM-inducing 'hits', uncovered previously by high-throughput screening, 33 specifically target either GATA3 and/or HDAC9. Unlike HDAC9, which has a catalytic site that can be easily targeted and blocked, blocking the function of a TF such as GATA3 (specifically, from binding) has not yet been accomplished.
As BRM is inactivated through both silencing and acetylation, identifying compounds that reverse both of these processes would be advantageous. Our data suggest that known inhibitors of the MAP kinase pathway are likely capable of activating BRM when it has been silenced or acetylated. Hence, these data raise questions regarding whether inhibitors of the upper MAP kinase pathway, such as clinically available Raf inhibitors (for example, Sorafenib) or perhaps EGFR inhibitors (Erlotinib (Tarceva) or Gefitinib (Iressa)), require restoration of BRM as a prerequisite for their anticancer functions, or perhaps their failure to restore BRM might underlie development of clinical resistance over time. Mechanisms of growth inhibition by kinase inhibitors are complex, and such an approach would depend not only on Rb, but also on the BRM homolog, BRG1, as well as other proteins. However, defining the role of BRM status as a function of these inhibitors will give us a better understanding of how and when these drugs should be used for ideal efficacy.
BRM is not only regulated by silencing and post-translational inactivation. 15, 25, 31 Its expression is also modulated by microRNA. 76 This complex regulation of BRM likely stems from the multitude of cellular processes with which BRM and SWI/SNF are involved, particularly growth control, differentiation and development. 3, 4 It is unclear why BRM is sometimes inactivated by acetylation while in other instances it is silenced by suppression. Interestingly, the MAP kinase pathway is able to induce BRM silencing and in other cases, BRM acetylation. As the MAP kinase pathway can control both BRM acetylation and silencing, this suggests that the BRM regulation pathway likely diverges below the level of the MAP kinase pathway. Although we believe that BRM acetylation completely inactivates BRM, it may only partially inhibit BRM, thereby restricting its function (it may bind to certain proteins and not others), whereas total BRM silencing ensures complete loss of BRM activity. Further, BRM acetylation and BRM sequencing might act sequentially, where if one mechanism can't silence BRM the other mechanism can.
Furthermore, it is unclear whether BRM is important for cancer development and why it is not simply mutated and eliminated like other anticancer genes. Perhaps BRM is not a target of cancer development, but instead is suppressed or acetylated because it happens to be collaterally impacted. Yet, arguing against this, SWI/ SNF and BRM have been tied to many cellular functions that oppose cancer development. This is most clearly demonstrated by the fact that re-expression of BRM ectopically, virally or pharmacologically, inhibits growth and induces a differentiatedlike morphology in essentially every cell line examined to date (B15). 35, 46, 47 Moreover, BRM is known to bind to Rb and the Rb family members, p107 and p130, to facilitate growth inhibition when it is co-expressed with Rb. 15, 16, 46, 47 This is further supported by BRM-null animal models, which show the loss of BRM produces cells that feature aberrant growth control and in which mice develop a far greater number of tumors when exposed to carcinogens. 25, 77 However, it is important to remember that reactivation of BRM represents the reversal of an epigenetic mechanism that likely regulates many other genes, and not only BRM. Hence, silencing via this mechanism may be a much more effective way to silence a cadre of genes rather than simply disrupting each gene individually. Although BRM silencing clearly can contribute to cancer development, it may not be the most important anticancer gene targeted by this overall mechanism.
By using a combination of specific HDAC inhibitors and an RNA interference approach (shRNA), we determined that HDAC3, HDAC4 and HDAC9 all regulate BRM. This is not surprising, as class 1 HDACs are known to recruit class 2 HDACs, 78 and HDAC3 is known to specifically interact with HDAC9. 63 We also showed that a different HDAC (HDAC2) underlies BRM acetylation and inactivation. In addition, as the function of HDACs are counterbalanced by HATs, we also investigated which HATs contribute to BRM regulation and found that KAT6A, KAT6B and KAT7 can induce BRM when ectopically expressed in BRMdeficient cell lines. Although some HATs are known to be frequently mutated or form hybrid transcripts in leukemias and other cancers, [79] [80] [81] [82] we did not find any such alterations in BRMdeficient cancer cells that might explain why BRM is silenced. Although it has been long appreciated that the HDAC inhibitors can restore BRM expression, but not necessarily BRM function, 25 it was not until the work of Bourachot and Muchardt 31 that it was understood why. They elegantly demonstrated most HDAC inhibitors cause acetylation of the C-terminus of BRM protein resulting in inactivation of BRM. Unlike BRM silencing where two HDACs can be linked to BRM expression, we found that only HDAC2 controlled BRM acetylation. Similarly, we found that KAT2B and KAT8 can drive BRM acetylation. Again, although HDAC2, KAT2B and KAT8 can be altered and thus become dysfunctional in cancer, 79, [81] [82] [83] sequencing the mRNAs of these three genes did not reveal any mutations in our BRM-deficient cancer cell lines. Although our unpublished work has revealed that BRM acetylation occurs in both cell lines and primary tumors, further investigation is required to determine whether this form of BRM inactivation occurs with any significant frequency.
The study described is limited by the current understanding within the field of cancer biology as to how both HATs and HDACs, especially class 2 HDACs, are regulated and in turn regulate other genes. Only now are we beginning to understand how these proteins are recruited to DNA regions where their modifications result in changes to the imprinting of chromatin. Such chromatin modifications are the underlying mechanisms to the histone code, which in turn underlies proper differentiation, development and normal cellular function. By first identifying some of the major proteins that impact the regulation of BRM, we are now in a position to begin investigating exactly how they contribute to the mechanism regulating BRM. Moreover, as epigenetic mechanisms are unlikely to evolve to regulate to just one gene, many additional genes may, in fact, be regulated by this same mechanism. Therefore, understanding the mechanism has broad implications in the field of epigenetics, and cancer biology.
The clinical reversal of the epigenetic regulation of an anticancer gene is a novel, emerging, therapeutic strategy that is potentially both effective and beneficial. Specifically, we show in the article that restoring BRM is a novel target for therapy. Currently, there is little known about how BRM is epigenetically silenced or inactivated via acetylation, hence in this research, we defined which HDACs and HATs underlie the regulation of BRM. More importantly, we identified proteins that could make a good target for therapy by examining which of these proteins might be selectively overexpressed in cancer cells. Before the best clinical targets for this purpose are clearly defined, it will likely require us to understand most of if not the entire mechanism of BRM regulation. Nevertheless, our work points toward HDAC9 being a good, potential, clinical target for therapy because it is: (1) selectively expressed in only a small subset of normal tissues thereby reducing the chance of toxicity if inhibited and (2) highly overexpressed in cancer cells. For these reasons, HDAC9 appears to be a viable and ideal target for therapy. As such, it is anticipated that clinically targeting HDAC9 will lead to the effective restoration of BRM and more importantly, pave the way for a novel avenue of targeted therapy, gene reactivation.
MATERIALS AND METHODS
Cell culture
All cells lines were obtained by American Type Culture Collection (Manassas, VA, USA) and were grown in RPMI media supplemented with 5% fetal bovine serum, 1% glutamax and 1% pen/strep. Cells were tested to be mycoplasma free, and the authenticity of the cell lines was confirmed by sequencing p53 in each cell line and matched to published p53 data. For all pharmacological treatments, cells were plated in six-well plates at about 60% confluency and were treated with appropriate compounds with selected doses. Compounds used for the analysis were MGCD0103 (Selleck Chemicals, Houston, TX, USA), MC1568 (Selleck Chemicals, Houston, TX, USA), RGFP963 (Repligen, Waltham, MA, USA), PD98059, PD169316 (Cayman Chemical, Ann Arbor, MI, USA). For RNA, cells were collected after 48 h, whereas for protein, cells were collected after 72 h of treatment and processed accordingly. For the transfection experiments, cells were plated in a T75 flask at 60% confluency and transfected with appropriate plasmid(s) using Polyplus Jetprime Reagent (VWR, Radnor, PA, USA), as per the manufacturer's instructions. Cells from the transfections were processed for both RNA and proteins after 72 h.
Growth inhibition assay
Cell lines were grown in six-well plates from a cell density of B10-15% and allowed to grow up to B95% confluent. Cell lines under different treatment regimens were counted daily for 5-7 days using an Accuri C6 flow cytometer (BD Biosciences, San Jose, CA, USA). Cell viability was determined by Trypan blue staining from parallel wells. Manual counts using a hemocytometer were done on day 1 and on the last day of each experiment to verify the end point cell numbers.
Western blots and qPCR
Cell pellets were lysed using Trizol reagent 84 and total mRNA isolated using the Sigma RNA extraction kit (Sigma-Aldrich, St Louis, MO, USA), as per the manufacturer's instructions. Complementary DNA was generated from 1 mg of RNA using Bio-Rad iScript kit (Bio-Rad, Hercules, CA, USA), following the manufacturer's instructions. QPCR was performed using RT Fast SYBR Green/ ROX qPCR Master Mix (SA Biosciences/Qiagen, Valencia, CA, USA) according to the following conditions: 95 1C for 10 min, and 40 cycles of 95 1C for 10 s and 60 1C for 30 s. Primers used for qPCR are listed in Supplementary  Table 3 . For western blot analysis, whole-cell lysates were extracted using Urea buffer (8.8 M urea, 5 M NaH 2 PO 4 , 1 M Tris, pH 8.0) as described in Reyes et al. 77 In all, 80 mg proteins were mixed with 6 Â Lamelli buffer and boiled for 10 min and then loaded in 4-15% Bio-Rad precast gel (Bio-Rad). Gels were run for 1 h at constant voltage of 150 V. Subsequently, proteins were transferred to a Millipore Immobilon-P membrane (Millipore, Billerica, MA, USA). Proteins were transferred for 1 h at constant current of 350 mA. For detection of BRM, a polyclonal anti-BRM antibody (1:500) was used. 25 Antirabbit acetylated-BRM antibody was a gift from Christian Muchardt, and was used at 1:500 dilution. 31 Polyclonal anti-HDAC antibodies were obtained from Biovision (Milpitas, CA, USA) and were used at 1:500 dilutions. A monoclonal anti-GATA3 antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and was used at 1:300 dilutions. Appropriate secondary antibody (GE Healthcare, Little Chalfont, UK) was used at 1:2000 dilutions. Glyceraldehyde 3-phosphate dehydrogenase antibody (GeneTex Inc., Irvine, CA, USA) was used as the loading control. Western blots were developed using ECL Prime western blot detection kit (GE Healthcare). Western blots were analyzed using ImageJ (National Institutes of Health (NIH), Bethesda, MD, USA) software. H460 and SW13 were used as positive and negative BRM expression controls, respectively, whereas the cell lines H661 and H441 (BRM-nonacetylated), and H460 and H157 (-acetylated) were used as controls for BRM acetylation studies.
Generation of RNA interference knockdowns pLKO.1 plasmids containing gene-specific or scrambled shRNA (control) were used in the analysis of BRM, HAT and HDAC (source: Open Biosystems, Thermo Scientific, Lafayette, CO, USA). All shRNAs were obtained from Open Biosystems and the catalog number for each shRNA is listed in the Supplementary Table 4 . For infection, cells were plated at about 30-40% confluency in 24-well plates and infected 2-3 times at 20 Â concentration for 16 h each time. Subsequently, cells were puromycin-selected for 3 days and knockdown efficiency was determined by qPCR and western blot.
HDAC9 overexpression study
For the analysis, cells were plated at B70-75% confluency in T75 flasks. shRNA-mediated knockdowns of GATA3 or MEF2D were conducted (as described above) in C33A and SW13 cell lines. HDAC9 was also transfected into these cells, and after 72-h RNA collected and processed as described above. QPCR was performed to determine the level of BRM, GATA3, MEF2D and HDAC9 mRNA expression after and before GATA3 and/or MEF2D shRNA knockdowns.
Nuclear run-on assay Nuclear run-ons were conducted as described previously. 61 
Immunohistochemical staining
Immunohistochemical staining was conducted as previously described. 25, 28, 85 Briefly, formalin-fixed paraffin-embedded tissue blocks (Providence Hospital, Southfield, MI, USA) were analyzed by immunohistochemical staining. Antigen retrieval for BRM, HDAC9 and GATA3 were performed using 10 mM Tris (pH 10), 10 mM sodium citrate buffer (pH 6.0), and 10 mM Tris with 1 mM EDTA and 0.05% Tween 20 (pH 8), respectively following the manufacturer's guidelines. Anti-BRM rabbit Ab is described in Glaros et al. 25 and used at dilution of 1:500; rabbit polyclonal anti-HDAC9 antibody (ab70954, Abcam, Cambridge, MA, USA) was used at a dilution of 1:50; the mouse monoclonal GATA3 Ab was used (sc-268, Santa Cruz Biotechnology) at a dilution of 1:50. A goat anti-rabbit or goat anti-mouse biotinylated secondary was used with these primary antibodies at 1:200 (GE Healthcare). Sections were incubated with primary antibodies for 2 h at room temperature, and with secondary antibodies for 1 h. We used an ABC staining kit with DAB/nickel detection reagent (BD Pharmingen, San Diego, CA, USA). Slides were counterstained with Harris hematoxylin for 2 min.
